AxoGen, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 159.01 million compared to USD 138.58 million a year ago. Net loss was USD 21.72 million compared to USD 28.95 million a year ago.

Basic loss per share from continuing operations was USD 0.51 compared to USD 0.69 a year ago. Diluted loss per share from continuing operations was USD 0.51 compared to USD 0.69 a year ago.